Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 26;10(33):12221-12229.
doi: 10.12998/wjcc.v10.i33.12221.

Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial

Yi-Jing Zhang  1 , Lin Yin  1 , Jun Li  2
Affiliations

Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial

Yi-Jing Zhang et al. World J Clin Cases. .

Abstract

Background: Increasing reports have demonstrated that recombinant human brain natriuretic peptide (rhBNP) can improve acute myocardial infarction (AMI) and heart failure. However, whether it can improve renal function and decrease the risk of contrast-induced nephropathy (CIN) in elderly AMI patients is still unclear.

Aim: To explore the effect of rhBNP on CIN in elderly AMI patients after percutaneous coronary intervention (PCI).

Methods: One hundred and thirty-one elderly AMI patients underwent PCI from January 2017 to July 2021. Patients were either given 1 mL of 0.9% normal saline/(kg/h) for 72 h after PCI (control group, n = 66) and or intravenous rhBNP [1.5 mg/kg followed by 0.0075 mg/(kg/min)] for 72 h (rhBNP treatment group, n = 65). Serum creatinine and cystatin C levels, creatinine clearance rate, and eGFR were measured at 24 h, 48 h, and 72 h after PCI. Research nurses collected data on handwritten forms, and then stored them in password-protected electronic databases.

Results: The creatinine clearance rate and eGFR were increased, while the creatinine and cystatin C levels were decreased significantly in the rhBNP treatment group compared to the control group at 48 h and 72 h. The incidence of CIN (P = 0.028) and acute heart failure (P = 0.017) also significantly decreased in the rhBNP group. No significant difference was noted between the two groups in cardiac death and recurrent AMI.

Conclusion: Early application of rhBNP could protect renal function and decrease the incidence of CIN after primary PCI and acute heart failure.

Keywords: Acute myocardial infarction; Contrast media; Myocardial infarction; Natriuretic peptide; Percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that there are no conflicting interests to disclose.

Figures

Figure 1
Figure 1
Study design. PCI: Percutaneous coronary intervention.
Figure 2
Figure 2
Trial profile. rhBNP: Recombinant human brain natriuretic peptide.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Eindhoven DC, Wu HW, Kremer SWF, van Erkelens JA, Cannegieter SC, Schalij MJ, Borleffs CJW. Mortality differences in acute myocardial infarction patients in the Netherlands: The weekend-effect. Am Heart J. 2018;205:70–76. - PubMed
    1. D'Errigo P, Seccareccia F, Barone AP, Fusco D, Rosato S, Maraschini A, Colais P, Casali G. Effectiveness of invasive reperfusion therapy and standard medical treatment in AMI. Acta Cardiol. 2010;65:645–652. - PubMed
    1. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U CULPRIT-SHOCK Investigators. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017;377:2419–2432. - PubMed
    1. Galal H, Shehta M, Attia S, Bastawy I. Comparing Trimetazidine with Allopurinol in Prevention of Contrast Induced Nephropathy After Coronary Angiography. J Saudi Heart Assoc. 2020;32:451–455. - PMC - PubMed
    1. Lian X, He W, Zhan H, Chen J, Tan N, He P, Liu Y. The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization. Int Urol Nephrol. 2019;51:2267–2272. - PubMed